September 26th 2025
The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant costs.
New Center Marks Aggressive Push into CGMP Manufacturing of Cell and Gene Therapies
December 2nd 2019Aiming to break the bottlenecks that are slowing commercialization of innovative therapies, a new $50-million center in Boston will develop both cell and viral vector products within a single facility.
GS1 Launches Messaging Standard for Verification of Product Identifiers
February 12th 2019GS1, a global supply-chain standards organization, launched a new messaging standard in collaboration with GS1 US to help meet the requirements of the US Drug Supply Chain Security Act (DSCSA) for salable returns of serialized prescription drugs.